Chris Simon/LinkedIn
Mar 6, 2026, 15:09
Chris Simon: Persona PLUS Receives FDA Clearance for Patent‑Protected Plasma Apheresis
Chris Simon, President and Chief Executive Officer at Haemonetics, Member of Board of Directors at Sotera Health Company and AdvaMed, shared on LinkedIn:
”Excited to receive FDA clearance for Persona PLUS, our proprietary, patent‑protected plasma apheresis technology.
This next‑generation, donor‑centric innovation advances the NexSys PCS platform, designed to safely improve yield, speed, and donor satisfaction.
Persona PLUS is supported by data from a randomized clinical trial with 30,000 plus donations from approximately 3,000 donors and was developed with our customers for the benefit of patients worldwide, with a clear focus on IgG yield and lowering cost per gram.”
Stay updated with Hemostasis Today.
-
Apr 22, 2026, 15:47Mohammed Alo: Being Fit Does Not Protect You from High LDL
-
Apr 22, 2026, 15:28ASH Committee Brings the Voice of Hematology to Capitol Hill
-
Apr 22, 2026, 15:22Stephen Pendergast: Are Universal Shelf Stable Blood Substitutes Finally Within Reach?
-
Apr 22, 2026, 14:51Mavis Agnes Kisakye: Reconnecting to Drive the Global Bleeding Disorders Agenda Forward
-
Apr 22, 2026, 14:48Augustina Isioma Ikusemoro: Not Every Antigen Speaks Loudly, But the Right Test Will Hear It
-
Apr 22, 2026, 14:47Karuna Kumar: Busting the Myth about Increasing Infection Risk by IV Iron
-
Apr 22, 2026, 14:46David Brown: Charting a New Path Forward for One Patient Facing Extraordinary Cardiac Challenges
-
Apr 22, 2026, 14:45Ney Carter Borges: Syphilis and Cardiovascular Risk – A Silent and Progressive Vascular Burden
-
Apr 22, 2026, 14:44Sanjay Ahuja – New CEO and Medical Director of Innovative Hematology